Patents by Inventor John Anthony Moliterni
John Anthony Moliterni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9394263Abstract: There are provided compounds of the formula wherein: V, W, X, Y, Z, R1, R2, R3, R4, R5 and R6 are described herein. The compounds are useful for the treatment of proliferative diseases, including cancer.Type: GrantFiled: August 6, 2013Date of Patent: July 19, 2016Assignee: F. HOFFMANN-LA ROCHE AGInventors: Andrew F. Donnell, Xiaochun Han, Robert Francis Kester, Norman Kong, Kang Le, Yan Lou, Christophe Michoud, John Anthony Moliterni, Stacy Remiszewski, Kenneth Carey Rupert, Weiya Yun
-
Publication number: 20150361059Abstract: There are provided compounds of the formula wherein: V, W, X, Y, Z, R1, R2, R3, R4, R5 and R6 are described herein. The compounds are useful for the treatment of proliferative diseases, including cancer.Type: ApplicationFiled: August 6, 2013Publication date: December 17, 2015Applicant: Hoffman-La Roche Inc.Inventors: Andrew F. Donnell, Xiaochun Han, Robert Francis Kester, Norman Kong, Kang Le, Yan Lou, Christophe Michoud, John Anthony Moliterni, Stacy Remiszewski, Kenneth Carey Rupert, Weiya Yun
-
Patent number: 8063085Abstract: The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.Type: GrantFiled: December 10, 2008Date of Patent: November 22, 2011Assignee: Hoffmann-La Roche Inc.Inventors: Shaoqing Chen, Nicholas J. S. Huby, Norman Kong, John Anthony Moliterni, Omar Jose Morales
-
Patent number: 7615634Abstract: Novel intermediate compounds are disclosed. These compounds are useful in the synthesis of 4-aminopyrimidine-5-one derivatives that inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). The 4-aminopyrimidine-5-one derivatives and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors.Type: GrantFiled: June 20, 2006Date of Patent: November 10, 2009Assignee: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Qingjie Ding, Nan Jiang, Allen John Lovey, John Anthony Moliterni, John Guilfoyle Mullin, Jr., Binh Thanh Vu, Peter Michael Wovkulich
-
Patent number: 7612212Abstract: The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.Type: GrantFiled: January 25, 2007Date of Patent: November 3, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Shaoqing Chen, Nicholas J. S. Huby, Norman Kong, Steven Gregory Mischke, John Anthony Moliterni, Hong Wang, Zhuming Zhang
-
Patent number: 7557221Abstract: This invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are described in this application. These compounds inhibit the enzymes MEK 1 and MEK2, protein kinases that are components of the MAP kinase signal transduction pathway and as such the compounds will have anti-hyperproliferative cellular activity.Type: GrantFiled: August 6, 2008Date of Patent: July 7, 2009Assignee: Hoffman-La Roche Inc.Inventors: Shaoqing Chen, Nicholas J. S. Huby, Norman Kong, John Anthony Moliterni, Omar Jose Morales
-
Publication number: 20090048452Abstract: This invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are described in this application. These compounds inhibit the enzymes MEK 1 and MEK2, protein kinases that are components of the MAP kinase signal transduction pathway and as such the compounds will have anti-hyperproliferative cellular activity.Type: ApplicationFiled: August 6, 2008Publication date: February 19, 2009Inventors: Shaoqing Chen, Nicholas J.S. Huby, Norman Kong, John Anthony Moliterni, Omar Jose Morales
-
Patent number: 7371869Abstract: The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.Type: GrantFiled: September 14, 2005Date of Patent: May 13, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Robert Alan Goodnow, Jr., Nicholas J. S. Huby, Norman Kong, Lee Apostle McDermott, John Anthony Moliterni, Zhuming Zhang
-
Publication number: 20070197617Abstract: The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.Type: ApplicationFiled: January 25, 2007Publication date: August 23, 2007Inventors: Shaoqing Chen, Nicholas J. S. Huby, Norman Kong, Steven Gregory Mischke, John Anthony Moliterni, Hong Wang, Zhuming Zhang
-
Patent number: 7157455Abstract: Novel 4-aminopyrimidine-5-one derivatives are disclosed. These compounds inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 4-aminopyrimidine-5-one derivatives.Type: GrantFiled: February 2, 2004Date of Patent: January 2, 2007Assignee: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Qingjie Ding, Nan Jiang, Allen John Lovey, John Anthony Moliterni, John Guilfoyle Mullin, Jr., Binh Thanh Vu, Peter Michael Wovkulich
-
Publication number: 20040162303Abstract: Novel 4-aminopyrimidine-5-one derivatives are disclosed. These compounds inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 4-aminopyrimidine-5-one derivatives.Type: ApplicationFiled: February 2, 2004Publication date: August 19, 2004Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Qingjie Ding, Nan Jiang, Allen John Lovey, John Anthony Moliterni, John Guilfoyle Mullin, Binh Thanh Vu, Peter Michael Wovkulich